According to this new research study on 'T Cell Therapy Market Forecast (2020 - 2030), Global and Regional Share, Trends, and Growth Opportunity Analysis - by Modality, Therapy Type, and Indication,' the T cell therapy market size was valued at US$ 2,754.00 million in 2022 and is expected to reach US$ 9,035.01 million by 2030. It is estimated to register a CAGR of 16.0% during 2020-2030.
One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.
The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.
The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.
Reasons to Buy
One of the most promising procedures of cancer treatment is T cell therapy, and every year, an increasing number of pre-clinical and clinical research is being conducted to increase its application. CAR T cell therapy has also generated interest among oncologists and academics. The growing burden of cancer worldwide and an increasing number of T cell therapy approvals drive the growth of the T cell therapy market. Also, rising number of car t-cell therapies in clinical trials is expected to fuel T cell therapy market growth in the coming years.
The current landscape for CAR T-cell therapies is promising, with multiple drug approvals, a rich pipeline, and many ongoing clinical trials. Pipelines of CAR T-cell therapies are in various stages of clinical development; major pharmaceutical companies are working to advance the pipeline space and future growth potential of the CAR T-cell therapy competitive domain.
- In November 2022, Peter MacCallum Cancer Centre and Cartherics Pty Ltd entered into a Collaborative Development Program Agreement (CDPA) to develop Cartherics' proprietary autologous CAR T cell therapy (CTH-001) for treating cutaneous T-cell lymphoma (CTCL). The key aspects of the collaborative research are setting up clinical-scale manufacturing of CTH-001 and conducting a Phase I clinical trial. It will initially enroll six patients with refractory CTCL.
- JW Therapeutics drug JWCAR029 is a CAR T cell product that targets CD19 and is intended to treat advanced lymphoma and leukemia. The molecule is currently in Phase II of development. JWCAR029 is initially being investigated for treating B-cell malignancies, focusing on relapsed and refractory DLBCL.
- Gilead Sciences drug KTE-X19 is an autologous CD19 CAR T-cell therapy under investigation. The drug is manufactured using the XLP process, including T-cell selection and lymphocyte enrichment. Lymphocyte enrichment is required in certain B-cell malignancies for which KTE-X19 is being studied. KTE-X19 is currently in Phase II clinical trials for the treatment of both adult and pediatric acute lymphocytic leukemia. The FDA has approved Brexucabtagene autoleucel (formerly KTE-X19; Tecartus) for treating adult patients with relapsed or refractory mantle cell lymphoma (MCL).
- ZUMA-3 is a Phase 1/2 study evaluating KTE-X19, an autologous anti-CD19 CAR T-cell therapy, in adult relapsed/refractory (R/R) B-cell acute lymphoblastic leukemia (B-ALL).
- Descartes-11, a mRNA CAR T-cell therapy, has moved into a Phase II clinical trial for newly diagnosed, high-risk multiple myeloma (MM) patients. Descartes-11 expresses CAR T-cell molecules transiently and avoids some characteristic toxicities of these therapeutic agents. A Phase I study (NCT03994705) of 18 patients has already been undertaken, and results showed no evidence of cytokine release syndrome or neurotoxicity-adverse events commonly associated with CAR T-cell treatment.
By Modality, T Cell Therapy Market-Based Insights
Based on modality, the T cell therapy market is segmented into research and commercialized. In 2022, the commercialized segment held the larger share of the market. Moreover, the same segment is expected to grow fastest during the forecast period. An increase in product launches and a rise in awareness about the benefits of T cell therapy for cancer treatment fueling the growth of the commercialized segment.By Therapy Type, T Cell Therapy Market -Based Insights
Based on therapy type, the T cell therapy market is bifurcated into CAR T cell therapy and T cell receptor (TCR)-based. In 2022, the CAR T cell therapy segment held the larger share of the market. Moreover, the same segment will grow at a significant growth rate during the forecast period. In the chimeric antigen receptor (CAR) T cell therapy technique, T cells obtained from patients are artificially bioengineered to express CARs that can identify and attach to the tumor cells. The companies are entering into strategic developments such as collaborations, expansions, agreements, partnerships, and new product launches by companies operating in the CAR T cell segment, fueling the T cell therapy market growth. For instance, in 2022, FDA approved CARVYKTI manufactured by Janssen Biotech, Inc. CARVYKTI is a kind of therapy called CAR-T-which stands for chimeric antigen receptor T cell. CARVYKTI (ciltacabtagene autoleucel) is a treatment used for adult patients with bone marrow cancer called multiple myeloma. CARVYKTI treats adult patients with relapsed or refractory multiple myeloma after four or more former lines of therapy, comprising a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.The World Health Organization (WHO), the European Cancer Patient Coalition, and the National Cancer Institute are a few of the major primary and secondary sources referred to while preparing the report on the T cell therapy market.
Reasons to Buy
- Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the T cell therapy market.
- Highlights key business priorities in order to assist companies to realign their business strategies.
- The key findings and recommendations highlight crucial progressive industry trends in the global T cell therapy market, thereby allowing players across the value chain to develop effective long-term strategies.
- Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
- Scrutinize in-depth global T cell therapy market trends and outlook coupled with the factors driving the market, as well as those hindering it.
- Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing and distribution.
Table of Contents
1. Introduction
2. Executive Summary
3. Research Methodology
4. T Cell Therapy Market Landscape
5. T Cell Therapy Market - Key Industry Dynamics
6. T Cell Therapy Market - Global Market Analysis
7. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Modality
8. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Therapy Type
9. Global T Cell Therapy Market - Revenue and Forecast to 2030 - by Indication
10. T Cell Therapy Market - Geographical Analysis
11. T Cell Therapy Market-Industry Landscape
12. Company Profiles
13. Appendix
Companies Mentioned
- Immunocore Holdings Plc
- Legend Biotech Corp
- Janssen Global Services LLC
- Gilead Sciences Inc
- Bristol-Myers Squibb Co
- Bluebird Bio Inc
- Novartis AG
- JW (Cayman) Therapeutics Co Ltd
- Cartesian Therapeutics Inc
- Innovent Biologics Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 138 |
Published | September 2023 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 2.75 Billion |
Forecasted Market Value ( USD | $ 9.04 Billion |
Compound Annual Growth Rate | 16.0% |
Regions Covered | Global |
No. of Companies Mentioned | 10 |